Piper Jaffray analyst Edward Tenthoff expects the next two years to be "transformative" for Array BioPharma (ARRY), with the company reporting pivotal data and likely gaining approval on wholly-owned MEK inhibitor binimetinib and BRAF inhibitor encorafenib. In addition, partner AstraZeneca (AZN) will report selumetinib data in uveal melanoma and file a new drug application this year resulting in royalty revenue to Array in 2016, the analyst tells investors today in a research note. Tenthoff reiterates an Overweight rating on the stock with a $15 price target.